

## **Domain Therapeutics launches dedicated bioSensAll™ website**

**[www.biosensall.com](http://www.biosensall.com) gives easier and quicker access to essential information about unique technology that helps predict pharmacological profile of new molecules**

**Montreal, Canada, May 10<sup>th</sup>, 2017** – Domain Therapeutics NA, a biopharmaceutical company specializing in the research and development of small molecules that target G protein-coupled receptors (GPCRs), one of the most important classes of drug targets, today announces the launch of a new dedicated website introducing its bioSensAll™ technology. This newly designed webpage offers quick and easy access to essential information as well as features, enabling a more comprehensive understanding of the bioSensAll™ technology and its applications.

bioSensAll™ is a homogenous, live-cell bioluminescence resonance energy transfer ([BRET](#))-based biosensor assay that enables GPCR and ligand signaling profiling. This new website has a clean uncluttered design and rich content, focused on providing users and potential users with clear information on how the technology can support drug development, from compound identification to choice of candidate. Information generated with bioSensAll™ could help better inform the selection of safer and more clinically effective molecules at the early stages of the drug discovery process. Ultimately, this could lead to improved drug quality and decreased risk during drug development.

"We are excited about our new website launch and the robust information it provides for partners to better understand Domain's unique bioSensAll™ technology," said Pascal Neuville, Domain's president. "We believe that this new site will allow our visitors to have a very informative experience as we continue to grow and develop our technologies and compounds in the GPCR space."

"Our bioSensAll™ technology is able to deliver an understanding of signaling pathways activated by a candidate molecule, thus predicting its pharmacological profile. This approach makes it possible to choose at a very early development stage, the molecule(s) with the required activity but which do not present side effects or induce tolerance to treatment. Our turnkey solution complements other strategies, so that bioSensAll™ may help reduce the attrition rate of early stage drug development," added Dr. Neuville.

The website will be updated on a regular basis and visitors are encouraged to explore resources on [www.biosensall.com](http://www.biosensall.com). This website is complementary to Domain Therapeutics' site which remains available and will also be updated regularly with company news.

### **About G protein-coupled receptors and biosensor technology**

G protein-coupled receptors (GPCRs) belong to the family of membrane receptors and constitute one of the main classes of therapeutic targets for many indications. The binding of a hormone or a specific ligand to a receptor's binding site activates one or several pathways for intracellular signaling. This enables the cell to provide an adapted response to the change in its environment. The many drugs that target GPCRs represent about 40% of all treatments on the market, but only address 15% of GPCRs.

The bioSensAll™ platform was originally developed through a pharma and academic consortium in the Quebec region (CQDM). A new and more powerful generation of the platform was recently developed by a team of researchers from the University of Montreal's Institute for Research in Immunology and Cancer (IRIC), led by Pr. Michel Bouvier, and from McGill University, led by Pr. Stéphane Laporte. Domain Therapeutics retains the exclusive commercialization rights of the technology.

[www.biosensall.com](http://www.biosensall.com)

### **About Domain Therapeutics**

Domain Therapeutics is a biopharmaceutical company based in Montreal, Canada and Strasbourg, France, dedicated to the discovery and early development of small molecules targeting GPCRs, one of the most important classes of drug targets. Domain Therapeutics identifies and develops new drug candidates, allosteric modulators and biased ligands through its innovative approach and distinctive technologies. The company provides access to its technologies through licenses, research and collaborative agreements and develops its own pipeline for major indications in central nervous system and metabolic disorders.

[www.domaintherapeutics.com](http://www.domaintherapeutics.com)

---

#### **Media contacts and analysts**

Andrew Lloyd & Associates  
Agnes Stephens | Sandra Régnavaque  
[agnes@ala.com](mailto:agnes@ala.com) | [sandra@ala.com](mailto:sandra@ala.com)

Tel: +44 1273 675 100

@ALA\_Group

---